Health · Guinea-Bissau

Hepatitis B Vaccine Trial in Guinea-Bissau Newborns Halted, Lead Researcher Says

By: Noha Nigm

The lead researcher of a US-backed hepatitis B vaccine trial in Guinea-Bissau newborns says it will not go ahead because governmental approval was not granted. The study, which drew global criticism over ethics and consent, was to be funded with $1.6m from the US CDC and matching private money.

A US-backed hepatitis B vaccine trial in newborns in Guinea-Bissau, which drew international criticism, has been halted, according to its lead researcher.

Danish researcher Frederik Schaltz-Buchholzer wrote on LinkedIn on Wednesday that it is "now clear" the study "will not move forward in Guinea-Bissau", adding that the team was not given the necessary governmental approval. Guinea-Bissau's health minister, Quinhin Nantote, had earlier rejected suggestions that the project would proceed, saying such claims were not remotely true.

The study was to be funded with $1.6m from the US Centers for Disease Control and Prevention, matched by another $1.6m from private partners including the Pershing Square Foundation and the Bluebell Foundation. Authorities in Guinea-Bissau now hold the researchers' vaccines, which were taken when offices of the Bandim Health Project were searched on Monday.

The researchers, who also include Christine Stabell Benn and Peter Aaby, had hypothesised that giving hepatitis B vaccine alongside live vaccines such as BCG could dampen a wider mortality benefit of the latter. Paul Offit, a vaccines expert at the Children's Hospital of Philadelphia, called the idea fanciful and said there was no evidence for it. He urged that the funding be used to vaccinate as many children as possible. Guinea-Bissau currently plans to introduce a universal birth dose in 2028.

Critics also raised consent concerns, because families declining to take part would not have received the vaccine. Danish researcher Henrik Støvring questioned how such consent could be considered non-coercive.

The World Health Organization reiterated that all infants should receive a first hepatitis B dose as soon as possible after birth, preferably within 24 hours. Schaltz-Buchholzer said the trial caused distrust among Bissau-Guineans, but stressed that both vaccination schedules are not dangerous. The CDC and the Danish researchers did not respond to questions on the funding or the criticism.

More reporting from Voice of Africans